An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer
- 15 May 2014
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 134 (2) , 331-337
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck CancerPLOS ONE, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapyRadiotherapy and Oncology, 2011
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast CancerClinical Cancer Research, 2010
- Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian CancerMolecular Cancer Therapeutics, 2010
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in CancerNucleic Acids Research, 2010
- Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor MicroenvironmentCancer Research, 2010
- Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian CancerJournal of Clinical Oncology, 2010
- Ovarian cancer: strategies for overcoming resistance to chemotherapyNature Reviews Cancer, 2003